[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":103},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100633584","serial-cardiac-magnetic-resonance-imaging-cmr-with-contrast-agents-and-biomarker-analysis-for-the-detection-of-cardiotoxicity-under-anthracycline-containing-cancer-therapy-100633584",false,"NCT07528586","Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy","Serial Cardiac Magnetic Resonance Imaging (CMR) With Contrast Agents and Biomarker Analysis for the Detection of Cardiotoxicity Under Anthracycline-containing Cancer Therapy - A Monocentric, Low Interventional Phase IV Pilot Study","CMR-Onko","Inclusion Criteria\n\n\\- Patients with a recommendation for antineoplastic therapy including at least four administrations of an anthracycline\n\nExclusion Criteria\n\n* Inability to provide informed consent\n* Prior administration of an anthracycline\n* Administration of cardiotoxic drugs within the last six months, such as:\n* High-dose cyclophosphamide (\\>1,000 mg\u002Fm² or \\>10 mg\u002Fkg)\n* HER2 inhibitors\n* VEGF inhibitors\n* BCR-ABL inhibitors\n* BRAF inhibitors\n* MEK inhibitors\n* Immune checkpoint inhibitors (CTLA-4 inhibitors, PD-1 inhibitors, PD-L1 inhibitors)\n* Planned invasive cardiac intervention during the study period\n* Cardiac involvement of an underlying disease, e.g. amyloidosis\n* Treatment with fewer than four administrations of anthracyclines\n* Treatment with a liposomal anthracycline formulation\n* Treatment in which anthracyclines are not administered in every chemotherapy cycle\n* Thoracic radiation involving the heart prior to anthracycline administration\n* Participation in another clinical study concurrently or within the last three months\n* Renal impairment with a GFR \\\u003C 30 ml\u002Fmin\u002F1.73 m²\n* Patients in the perioperative phase of liver transplantation\n* Contraindications to cardiac magnetic resonance imaging, such as metallic implants (e.g. cardiac pacemaker)\n* Pregnancy or breastfeeding\n* Hypersensitivity or intolerance to gadolinium-based contrast agents\n* Vulnerable populations (individuals unable to protect their own interests, prisoners)","ALL","18 Years",{"count":20,"type":21},93,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of the trial is the early detection of cardiotoxicity in patients treated with anthracycline-based chemotherapy. Current diagnostics, such as troponin T, NT-pro-BNP, electrocardiogram, and echocardiography, are not able to identify early myocardial damage. Therefore, this study aims to identify early myocardial damage by using cardiac magnetic resonance imaging.\n\nThe primary endpoint of this study is the change in relaxation times in CMR before, during, and after therapy.\n\nFurthermore, the study analyzes:\n\n* other abnormal results in CMR\n* changes in troponin T and NT-pro-BNP\n* changes in global longitudinal strain in echocardiography and correlation with results of CMR\n* detection of new biomarkers in blood, urine, or stool",[27,28],"Cardiotoxicity","Anthracycline-induced Cardiotoxicity",[30,31,32],"anthracycline","cardiotoxicity","cardiac magnetic resonance imaging","RECRUITING","2026-04-07",{"date":36,"type":37},"2026-04-14","ACTUAL",{"date":39,"type":37},"2026-03-04",{"date":41,"type":21},"2030-03",{"name":43,"class":44},"Robert Bosch Gesellschaft für Medizinische Forschung mbH (RBMF)","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":5},"100604180","clinical-evaluation-of-a-new-platform-for-bi-manual-endoscopic-resection-in-the-rectum-and-sigma-endotem-100604180","NCT07146165","Clinical Evaluation of a New Platform for Bi-manual Endoscopic Resection in the Rectum and Sigma (EndoTEM)","EndoTEM","Inclusion Criteria:\n\n* Availability of written informed consent from the patient\n* Age \\> 18 years\n* Adenoma or early carcinoma \\> 2 cm in the rectum or distal sigmoid colon with indication for endoscopic en bloc resection using endoscopic submucosal dissection\n\nExclusion Criteria:\n\n* Informed consent not possible (e.g., language barrier)\n* Stenoses or fistulas in the anal region\n* Distance to the anocutaneous line ≤ 2 cm\n* Distance to the anocutaneous line \\> 20 cm\n* Individual medical assessment required for patients taking anticoagulant medication, in accordance with current ESGE guidelines\n* Pregnancy or breastfeeding\n* Vulnerable individuals",{"count":54,"type":21},30,[24],"The goal of this clinical trial is to determine whether the use of the EndoTEM system during the endoscopic removal of polyps in the distal colon is feasible and safe.\n\nThe main questions it aims to answer are:\n\n* Is the use of the EndoTEM system during the endoscopic removal of polyps in the distal colon feasible (i.e., does it enable complete resection of the polyp)?\n* Is the use of the EndoTEM system during the endoscopic removal of polyps in the distal colon safe?\n\nParticipants will:\n\n* be treated with the EndoTEM system during the endoscopic submucosal dissection of polyps in the distal colon.\n* answere questionnaires on fecal continence and quality of life before and after the intervention.\n* be treated following standard clinical procedures before, during and after the endoscopic removal.",[58,59],"Adenoma Colon Polyp","Adenoma Colon",[61,62,63,64,65],"endoscopic submucosal dissection","endoscopic en bloc resection","EndoTEM system","endoscopic portsystem","ESD","2026-03-30",{"date":68,"type":37},"2026-03-31",{"date":70,"type":37},"2025-10-02",{"date":72,"type":21},"2028-08",{"name":43,"class":44},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":80,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":82,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":90,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":4},"100625469","auricular-acupressure-for-perioperative-anxiety-and-pain-in-therapeutic-breast-surgery-rosa-100625469","NCT07423039","Auricular Acupressure for Perioperative Anxiety and Pain in Therapeutic Breast Surgery (ROSA)","Auricular Acupressure for Reducing Perioperative Anxiety and Pain in Therapeutic Breast Surgery Following an Initial Breast Cancer Diagnosis","ROSA","Inclusion Criteria:\n\n* Female gender\n* Breast cancer patients undergoing therapeutic breast surgery at Robert Bosch Hospital following an initial diagnosis.\n* Signed informed consent form.\n\nExclusion Criteria:\n\n* An anxiety disorder that has been diagnosed within the last 12 months.\n* A mental state that, in the opinion of the investigator, prevents the patient from participating in the study.\n* Use of hearing aids.\n* Skin irritations or eczema in the ear.\n* Pregnancy\n* Insufficient knowledge of German\n* Unwillingness to store and share personal medical data within the framework of the protocol\n* Missing or incomplete declaration of consent\n* Receipt of acupuncture treatment (including NADA ear acupuncture or acupressure) in the last three months.","FEMALE","99 Years",{"count":85,"type":21},66,[24],"This randomized, controlled, single-center trial investigates the effects of auricular acupressure, administered according to the National Acupuncture Detoxification Association (NADA) protocol, on perioperative anxiety and pain in patients with a first diagnosis of breast cancer undergoing therapeutic breast surgery. Participants receiving auricular acupressure according to the NADA protocol will be compared with patients receiving standard care alone.",[89],"Breast Cancer Females",[91,92,93],"Anxiety","Pain","NADA Auricular Acupressure","NOT_YET_RECRUITING","2026-02-13",{"date":97,"type":37},"2026-02-20",{"date":99,"type":21},"2026-02-01",{"date":101,"type":21},"2027-12-31",{"name":43,"class":44},""]